Cargando…

Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV

The interplay of artemether-lumefantrine (AL) and atazanavir-ritonavir (ATVr) with Cytochrome P (CYP) 3A4 isoenzyme and QTc-interval may spawn clinically significant drug interactions when administered concomitantly. Cardiotoxicity and other adverse effects associated with interaction between AL and...

Descripción completa

Detalles Bibliográficos
Autores principales: Usman, Sikiru Olatunji, Oreagba, Ibrahim Adekunle, Busari, AbdulWasiu, Akinyede, Akinwumi, Adewumi, Ololade, Kadri, Michael Rotimi, Hassan, Olayinka, Fashina, Yinka Adeyemi, Agbaje, Esther Oluwatoyin, Akanmu, Sulaimon Alani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177448/
https://www.ncbi.nlm.nih.gov/pubmed/35693439
http://dx.doi.org/10.1016/j.jsps.2022.02.010
_version_ 1784722889693462528
author Usman, Sikiru Olatunji
Oreagba, Ibrahim Adekunle
Busari, AbdulWasiu
Akinyede, Akinwumi
Adewumi, Ololade
Kadri, Michael Rotimi
Hassan, Olayinka
Fashina, Yinka Adeyemi
Agbaje, Esther Oluwatoyin
Akanmu, Sulaimon Alani
author_facet Usman, Sikiru Olatunji
Oreagba, Ibrahim Adekunle
Busari, AbdulWasiu
Akinyede, Akinwumi
Adewumi, Ololade
Kadri, Michael Rotimi
Hassan, Olayinka
Fashina, Yinka Adeyemi
Agbaje, Esther Oluwatoyin
Akanmu, Sulaimon Alani
author_sort Usman, Sikiru Olatunji
collection PubMed
description The interplay of artemether-lumefantrine (AL) and atazanavir-ritonavir (ATVr) with Cytochrome P (CYP) 3A4 isoenzyme and QTc-interval may spawn clinically significant drug interactions when administered concomitantly. Cardiotoxicity and other adverse effects associated with interaction between AL and ATVr were evaluated in patients with HIV infection and malaria comorbidity. In a two-arm parallel study design, six doses of AL 80/480 mg were administered to 20 participants [control-arm (n = 10) and ATVr-arm (n = 10)], having uncomplicated Falciparum malaria, at intervals of 0, 8, 24, 36, 48 and 60 h respectively. Participants in the control arm took only AL while those in ATVr-arm took both AL and ATVr-based ART regimen. Electrocardiography, adverse events monitoring and blood tests were carried out for each of them at pre and post doses of AL. Data obtained were analyzed. QTc-interval was significantly increased in the ATVr-arm (0.4079 ± 0.008 to 0.4215 ± 0.007 s, p = 0.008) but not in the control-arm (0.4016 ± 0.018 to 0.4024 ± 0.014 s, p = 0.962). All values were, however, within normal range [0.36 – 0.44 / 0.46 s (male/female)]. General body weakness and chest pain were new adverse events reported, at post-dose of AL, in the ATVr-arm but not in the control-arm. There was no significant change (p > 0.05) in the plasma levels of creatinine, alanine aminotransferase, aspartate aminotransferase and hemoglobin at post-dose compared to pre-dose of AL in both arms of study. Concomitant administration of artemether-lumefantrine with atazanavir-ritonavir-based regimen is potentially cardiotoxic but not associated with clinically significant renal, blood nor liver toxicities. They must be used with caution.
format Online
Article
Text
id pubmed-9177448
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91774482022-06-10 Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV Usman, Sikiru Olatunji Oreagba, Ibrahim Adekunle Busari, AbdulWasiu Akinyede, Akinwumi Adewumi, Ololade Kadri, Michael Rotimi Hassan, Olayinka Fashina, Yinka Adeyemi Agbaje, Esther Oluwatoyin Akanmu, Sulaimon Alani Saudi Pharm J Original Article The interplay of artemether-lumefantrine (AL) and atazanavir-ritonavir (ATVr) with Cytochrome P (CYP) 3A4 isoenzyme and QTc-interval may spawn clinically significant drug interactions when administered concomitantly. Cardiotoxicity and other adverse effects associated with interaction between AL and ATVr were evaluated in patients with HIV infection and malaria comorbidity. In a two-arm parallel study design, six doses of AL 80/480 mg were administered to 20 participants [control-arm (n = 10) and ATVr-arm (n = 10)], having uncomplicated Falciparum malaria, at intervals of 0, 8, 24, 36, 48 and 60 h respectively. Participants in the control arm took only AL while those in ATVr-arm took both AL and ATVr-based ART regimen. Electrocardiography, adverse events monitoring and blood tests were carried out for each of them at pre and post doses of AL. Data obtained were analyzed. QTc-interval was significantly increased in the ATVr-arm (0.4079 ± 0.008 to 0.4215 ± 0.007 s, p = 0.008) but not in the control-arm (0.4016 ± 0.018 to 0.4024 ± 0.014 s, p = 0.962). All values were, however, within normal range [0.36 – 0.44 / 0.46 s (male/female)]. General body weakness and chest pain were new adverse events reported, at post-dose of AL, in the ATVr-arm but not in the control-arm. There was no significant change (p > 0.05) in the plasma levels of creatinine, alanine aminotransferase, aspartate aminotransferase and hemoglobin at post-dose compared to pre-dose of AL in both arms of study. Concomitant administration of artemether-lumefantrine with atazanavir-ritonavir-based regimen is potentially cardiotoxic but not associated with clinically significant renal, blood nor liver toxicities. They must be used with caution. Elsevier 2022-05 2022-02-25 /pmc/articles/PMC9177448/ /pubmed/35693439 http://dx.doi.org/10.1016/j.jsps.2022.02.010 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Usman, Sikiru Olatunji
Oreagba, Ibrahim Adekunle
Busari, AbdulWasiu
Akinyede, Akinwumi
Adewumi, Ololade
Kadri, Michael Rotimi
Hassan, Olayinka
Fashina, Yinka Adeyemi
Agbaje, Esther Oluwatoyin
Akanmu, Sulaimon Alani
Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title_full Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title_fullStr Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title_full_unstemmed Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title_short Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
title_sort evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with hiv
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177448/
https://www.ncbi.nlm.nih.gov/pubmed/35693439
http://dx.doi.org/10.1016/j.jsps.2022.02.010
work_keys_str_mv AT usmansikiruolatunji evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT oreagbaibrahimadekunle evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT busariabdulwasiu evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT akinyedeakinwumi evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT adewumiololade evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT kadrimichaelrotimi evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT hassanolayinka evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT fashinayinkaadeyemi evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT agbajeestheroluwatoyin evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv
AT akanmusulaimonalani evaluationofcardiotoxicityandotheradverseeffectsassociatedwithconcomitantadministrationofartemetherlumefantrineandatazanavirritonavirbasedantiretroviralregimeninpatientslivingwithhiv